Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions.
Key Growth Drivers and Opportunities
Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion.
Challenges
The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress.
Innovation and Expansion
EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial
In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco.
Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate.
With India’s First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard
In March 2025, India’s first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK).
Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals.
Inventive Sparks, Expanding Markets
The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.